After a year-long search, Adamis has a partner to market its EpiPen competitor
July 02, 2018 at 10:35 AM EDT
Shares of biotech Adamis Pharmaceuticals Corp. soared more than 35% Monday, after the company said its search for a commercial partner for its competitor to Mylan N.V.’s EpiPen allergic reaction treatment is over.
